ANTI OBESITY THERAPIES
Weight-loss medicines: Biocon eyes a $100 billion jackpot with weighty pivot
Weight-loss drugs: Biocon Ltd. is shifting focus to anti-obesity therapies as patents for key medications expire, leading to a surge in generic supply. The Bengaluru-based company secured UK approval for the first generic version of liraglutide injectible, positioning itself as a leader in this evolving market.
Eli Lilly in advanced clinical trials for its weight-loss pill
Eli Lilly has commenced phase three clinical trials in India for a new oral weight-loss drug called orforglipron. The trials aim to assess its safety and efficacy compared to insulin glargine in individuals with Type 2 diabetes and obesity or overweight at an increased cardiovascular risk. The company's spokesperson in India mentioned ongoing clinical studies on novel products, including orforglipron.
Novo Nordisk to buy Cardior Pharma for up to $1 billion
Novo Nordisk A/S bought Cardior Pharmaceuticals for $1 billion to enhance cardiovascular treatments. Cardior's microRNA-targeting therapies aim to improve heart function, aligning with Novo's focus on diabetes and obesity history.
AstraZeneca to buy Amolyt Pharma for $1.05 bln to boost rare-disease portfolio
AstraZeneca announced its acquisition of Amolyt Pharma, a company focused on endocrine diseases, for $1.05 billion in cash. This move aims to strengthen AstraZeneca's rare diseases portfolio. Amolyt Pharma, based in France, is in the late-stage development of a therapy for hypoparathyroidism called eneboparatide.
India pharma companies develop versions of Wegovy to get in on weight-loss windfall
Indian drugmakers are developing their versions of Novo Nordisk's weight-loss treatment, Wegovy, aiming to capitalize on the growing weight-loss market, expected to reach $100 billion a year by the end of the decade. Companies like Sun Pharma, Cipla, Dr Reddy's, and Lupin are working on Wegovy alternatives as Novo Nordisk struggles to meet global demand.
What other health conditions might weight-loss drugs treat?
New data suggests that semaglutide may also cut the risk of stroke or heart attack, and may delay the progression of kidney disease in diabetes patients.
- Go To Page 1
Cipla vows to crack diabetes segment with licensed branded portfolio
"Cipla historically has always been a big respiratory and acute player but not that big in the diabetes area," said Umang Vohra, managing director and global CEO of Cipla in an interview to ET.
Go for test for TB, other conditions if cough persists for more than 2-3 weeks: Revised clinical guidance for Covid patients
The revised guidelines continue to recommend emergency use authorization (EUA) or off-label use of remdesivir in patients with "moderate to severe" disease and those with no renal or hepatic dysfunction within 10 days of the onset of any symptom.
Covid treatment: Govt issues revised guidelines on use of drugs, therapies
The revised guidelines continue to recommend emergency use authorization (EUA) or off-label use of remdesivir in patients with "moderate to severe" disease and those with no renal or hepatic dysfunction within 10 days of the onset of any symptom.
France approves antibody therapy for high-risk Covid cases
The independent public health body HAS Friday night announced "a greenlight for the preventive use of Evusheld... for patients with a very high-risk of contracting a severe form of Covid-19".
How to stay away from heart disease, BP, obesity, diabetes? Answer is in your food
Choose the right anti-inflammatory foods, and you may be able to reduce your risk of illness.
India's most purchased drugs in the last decade are for cardiac ailments, diabetes
At around Rs 21,000 crore annually, cardiac medication forms the biggest therapy of drugs being bought by Indians today. A decade ago, it was a third of its size and the second largest-therapy by sales. At around Rs 16,000 crore, anti-diabetes medication today is the fourth-largest therapy of drugs sold in the country.
65 yr old man becomes 1st Covid patient to get antibody cocktail at Apollo in Delhi
As part of this single dose infusion-based treatment, patients with mild to moderate symptoms, are offered a cocktail of Casirivimab and Imdevimab, that is said to reduce their chance of hospitalisation by 70 per cent.
'Obesity paradox' decoded: Being overweight increases risk of diabetes but helps improve survival in cancer patients
WHO estimates at least 2.8 million people die each year as a result of being overweight or obese.
With hyper-competitive workplaces, should mental illness be treated like any other ailment?
One of every 10 people in India has a mental illness, according to a survey by Bengaluru’s National Institute of Mental Health & Neuro Sciences (NIMHANS).
Five diabetes drugs in top-10 selling list; overtakes anti-infective, antibiotic meds
Insulin brand Human Mixtard, oral formulation Glycomet GP, insulin Lantus, oral formulations Galvus Met and Janumet are now in the top-selling list of drugs in the country.
High cholesterol fuels growth and spread of breast cancer
The research for the first time explains the link between high cholesterol and breast cancer, especially in post-menopausal women.
Sunday ET: Obesity fuels growth of food outlets as well as weight-loss clinics
A nation bursting with 60 mn obese people is fuelling growth of 2 mkts: one the food that makes them fat, and another that helps them get back in shape.
Hygiene Hypothesis: Banishing germs from your life can make you seriously ill
Evidence accumulates in favour of the hygiene hypothesis, which says that banishing germs from your life can make you seriously ill.
Load More
